Induced-viscosity nutritional emulsions
    1.
    发明申请
    Induced-viscosity nutritional emulsions 审中-公开
    诱导粘度营养乳液

    公开(公告)号:US20070141124A1

    公开(公告)日:2007-06-21

    申请号:US11642033

    申请日:2006-12-19

    IPC分类号: A61K47/00

    摘要: Disclosed are induced viscosity nutritional emulsions comprising (A) protein having a protein-bound methionine sulfoxide content of 8% or less of the total protein-bound methionine, on a molar basis, (B) fat, and (C) an induced viscosity fiber system that provides the emulsion with a packaged viscosity of less than 300 cps and an induced viscosity following consumption of at least 300 cps, wherein the induced viscosity nutritional emulsion is an oil-in-water emulsion. It has been found that product stability is improved and shelf-life increased by selection of those protein sources having a low methionine sulfoxide content.

    摘要翻译: 公开了诱导粘度营养乳液,其包含(A)蛋白质结合的甲硫氨酸亚砜含量为总蛋白质结合的甲硫氨酸的8%或更低(基于摩尔)的蛋白质(B)脂肪,和(C)诱导粘度纤维 系统,其提供具有小于300cps的包装粘度和消耗至少300cps的诱导粘度的乳液,其中诱导粘度营养乳液是水包油乳液。 已经发现,通过选择具有低甲硫氨酸亚砜含量的那些蛋白质源,产物稳定性提高并且保质期增加。

    Treatment of mucositis
    2.
    发明申请

    公开(公告)号:US20060105985A1

    公开(公告)日:2006-05-18

    申请号:US11318677

    申请日:2005-12-27

    IPC分类号: A61K31/7076 A61K31/7072

    摘要: Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas. It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof.

    System-Initiated Speech Interaction
    4.
    发明申请
    System-Initiated Speech Interaction 有权
    系统启动的语音交互

    公开(公告)号:US20110301958A1

    公开(公告)日:2011-12-08

    申请号:US12794068

    申请日:2010-06-04

    IPC分类号: G10L21/00

    CPC分类号: G10L15/22 G06F9/451

    摘要: Whenever an event occurs on a computing system which will accept a response from a user of the system, the system automatically determines whether or not to enable speech interaction with the system for the event response. Whenever speech interaction is enabled with the system for the event response, the system provides a notification to the user which informs the user of the event and their options for responding thereto, where these options include responding verbally. Whenever the user responds within a prescribed period of time via a voice command (VC), the system attempts to recognize the VC. Whenever the VC is successfully recognized, the system responds appropriately to the VC.

    摘要翻译: 每当事件发生在将接受来自系统的用户的响应的计算系统时,系统自动地确定是否允许与系统进行语音交互以用于事件响应。 无论何时当系统为事件响应启用语音交互时,系统向用户提供通知用户事件及其响应选项,其中这些选项包括口头回应。 无论何时用户通过语音命令(VC)在规定的时间内作出响应,系统会尝试识别VC。 每当VC被成功识别时,系统将对VC进行适当的响应。

    System-initiated speech interaction
    6.
    发明授权
    System-initiated speech interaction 有权
    系统发起的语音交互

    公开(公告)号:US08600763B2

    公开(公告)日:2013-12-03

    申请号:US12794068

    申请日:2010-06-04

    IPC分类号: G10L21/00

    CPC分类号: G10L15/22 G06F9/451

    摘要: Whenever an event occurs on a computing system which will accept a response from a user of the system, the system automatically determines whether or not to enable speech interaction with the system for the event response. Whenever speech interaction is enabled with the system for the event response, the system provides a notification to the user which informs the user of the event and their options for responding thereto, where these options include responding verbally. Whenever the user responds within a prescribed period of time via a voice command (VC), the system attempts to recognize the VC. Whenever the VC is successfully recognized, the system responds appropriately to the VC.

    摘要翻译: 每当事件发生在将接受来自系统的用户的响应的计算系统时,系统自动地确定是否启用与系统的语音交互以用于事件响应。 无论何时当系统为事件响应启用语音交互时,系统向用户提供通知用户事件及其响应选项,其中这些选项包括口头回应。 无论何时用户通过语音命令(VC)在规定的时间内作出响应,系统会尝试识别VC。 每当VC被成功识别时,系统将对VC进行适当的响应。

    TREATMENT OF MUCOSITIS
    7.
    发明申请
    TREATMENT OF MUCOSITIS 审中-公开
    治疗骨质疏松

    公开(公告)号:US20080081796A1

    公开(公告)日:2008-04-03

    申请号:US11931613

    申请日:2007-10-31

    摘要: Disclosed are compositions and methods for alleviating mucositis, wherein said methods and compositions are directed to the formulation or use of selected nucleoside derivatives, especially ADP-ribose, that conform to the general formula A-B-X and pharmaceutically acceptable salts thereof, wherein “A” is a nucleoside structure selected from adenosine, guanosine, and uridine; “B” is a diphosphate linkage attached to the 5′ carbon of the nucleoside ribose moiety; and “X” is attached to B an is a moiety selected from hydrogen, furanose, or pyranose. Also disclosed are pharmaceuticals and nutritional liquid embodiments thereof, including lozenges, mouthwashes, or other product forms that effectively coat the oral, laryngeal or other mucosal areas. It has been found that these compositions and methods effectively alleviate mucositis in susceptible individuals, especially when administered prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof.

    摘要翻译: 公开了用于缓解粘膜炎的组合物和方法,其中所述方法和组合物涉及配制或使用符合通式ABX及其药学上可接受的盐的选定的核苷衍生物,特别是ADP-核糖,其中“A”是 选自腺苷,鸟苷和尿苷的核苷结构; “B”是连接到核苷核糖部分的5'碳上的二磷酸键; 和“X”连接于B an是选自氢,呋喃糖或吡喃糖的部分。 还公开了其药物和营养液体实施方案,包括有效地涂覆口腔,喉部或其他粘膜区域的锭剂,漱口剂或其它产品形式。 已经发现,这些组合物和方法有效地缓解易感个体中的粘膜炎,特别是在通常与粘膜炎发展相关的治疗之前,期间或之后施用,例如某些化学疗法,放射疗法或其组合时。